News | Sutro Biopharma, Inc.

Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize? – InVivo

Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize? – InVivo https://invivo.pharmamedtechbi.com/IV005100/Cancers-NextGen-Smart-Bomb-Who-Will-Be-First-To-Weaponize ...

Biotechnology: Saving Lives & Transforming Healthcare in the 21st Century

Events

Biotechnology: Saving Lives & Transforming Healthcare in the 21st Century Modern biotechnology is a young industry. But in just a few decades, the entrepreneurs, scientists, researchers and investors working in this field have firmly established themselves at the...

Sutro Appoints Lobacki as Director; Leonard, Krishnan & Levy as Advisors

Press Releases

Sutro Appoints Lobacki as Director; Leonard, Krishnan & Levy as Advisors SOUTH SAN FRANCISCO, April 27, 2017 –Sutro Biopharma Inc. is adding an expert in drug commercialization to its board of directors, appointing clinical and scientific advisors and promoting a...

American Association for Cancer Research (AACR) 2017 – Poster

Presentations

American Association for Cancer Research (AACR) 2017 – Poster Characterization and pre-clinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies 2017 combined MM and NHL AACR...

Sutro ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival in Tumor Models

Press Releases

Sutro ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival in Tumor Models SOUTH SAN FRANCISCO, April 3, 2017 – STRO-001, an antibody drug conjugate developed by Sutro Biopharma Inc., demonstrated potent anti-tumor activity in multiple...

SutroVax Announces Closing of $64M via Series B Financing

News

SutroVax Announces Closing of $64M via Series B Financing Foster City, CA, March 21, 2017 – SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious...